Home Vision Monitoring For Progression to Neovascular AMD Using the ForeseeHome Device Study
This study is currently recruiting participants.
The overall objective of this study is to determine if home monitoring using the comprehensive visual field and telemedicine solution based on the ForeseeHome device (referred to as the ForeseeHome comprehensive solution) in patients at high risk of progression to neovascular AMD improves detection of progression to choroidal neovascularization (CNV) when compared with standard care.
- Male or female participant between 55 and 90 years of age. Participants must have bilateral large drusen (? 125 microns) or large drusen in one eye (study eye) and advanced AMD (neovascular AMD or central geographic strophy) in the fellow eye as determined by their study ophthalmologist.
- Study eye(s) must have best corrected visual acuity 20/60 or better (at least 54 letters).
- Participant must be able to successfully demonstrate their ability to comprehend instructions and use of the ForeseeHome device (a ForeseeHome device will be available at the NY Eye and Ear Infirmary for the participant to demonstrate their ability).
Dr. Richard Rosen, Retina Vitreous Specialist
Melissa Rivas, Research Coordinator at 212-614-8386
> Current Research
> Clinical Trials in Ophthalmology
>Home Vision Monitoring For Progression to Neovascular AMD Using the ForeseeHome Device Study